Sugi Predict

Sugi Predict / Compounds / SCHEMBL221687

SCHEMBL221687

SCHEMBL221687

CS(=O)(=O)Nc1ccc(F)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.48
▸ KMT2A Q03164 2/20 0.47
▸ KEAP1 Q14145 1/20 0.47
▸ CCR2 P41597 1/20 0.46
▸ MPO P05164 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ NEU3 Q9UQ49 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ P2RY4 P51582 1/20 0.44
▸ KCNK2 O95069 1/20 0.44
▸ FABP3 P05413 1/20 0.44
▸ FABP4 P15090 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31046886 1.00 METAP2 (0.53) METAP2ALDH1A1KDM4EKMT2AKEAP1
SCHEMBL221906 0.87 ACLY (0.49) METAP2ALDH1A1KDM4EKMT2AKEAP1
SCHEMBL222213 0.81 METAP2 (0.68) METAP2ALDH1A1KDM4EKMT2AMCL1
SCHEMBL219601 0.80 ALDH1A1 (0.71) METAP2ALDH1A1KDM4EKMT2AMCL1
SCHEMBL219920 0.80 ACLY (0.66) METAP2ALDH1A1KDM4EKMT2ACCR2
SCHEMBL221627 0.80 KMT2A (0.49) METAP2ALDH1A1KDM4EKMT2AMCL1
SCHEMBL30100431 0.80 ACLY (0.66) METAP2ALDH1A1KDM4EKMT2ACCR2
SCHEMBL28047975 0.80 KDM4E (0.50) METAP2ALDH1A1KDM4EKMT2ACCR2
SCHEMBL23877629 0.80 CDK2 (0.46) METAP2ALDH1A1KMT2ACCR2MCL1
SCHEMBL3746656 0.80 KDM1A (0.65) ALDH1A1KDM4EKMT2AMPOMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 — — US disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 — — US disclosed
CN-112204008-B Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives 奥索生物公司 2024-07-05 — — CN disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed
CN-112204008-A Sulphonylaminobenzylamide and sulphonylaminobenzamide derivatives 吉利德科学公司 2021-01-08 — — CN disclosed
EP-2838900-B1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2019-08-21 — — EP disclosed
EP-2838900-B1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2019-08-21 — — EP disclosed
US-10174038-B2 Compounds and methods for antiviral treatment GILEAD SCIENCES, INC. (US) 2019-01-08 — — US disclosed
US-20130273037-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. 2013-10-17 — — US disclosed
US-8486938-B2 Pyrazolo[1,5-a]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2013-07-16 — — US disclosed
US-8486938-B2 Pyrazolo[1,5-a]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2013-07-16 — — US disclosed
US-8486938-B2 Pyrazolo[1,5-a]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2013-07-16 — — US disclosed
EP-2585467-A1 PYRAZOLO [1, 5 -A]PYRIMIDINES AS ANTIVIRAL AGENTS Gilead Sciences, Inc. (US) 2013-05-01 — — EP disclosed
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-01-05 — — US disclosed
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-01-05 — — US disclosed
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-01-05 — — US disclosed
WO-2011163518-A1 PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2011-12-29 — — WO disclosed
WO-2011163518-A1 PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B METAP2 2660/4885ALDH1A1 245/4885KDM4E 3158/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B METAP2 2660/4885ALDH1A1 245/4885KDM4E 3158/4885
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT TYMP, ZC3HAV1, TYMS METAP2 1647/4885ALDH1A1 1823/4885KDM4E 2069/4885
US-20130273037-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT ZC3HAV1, SARS1, MAVS METAP2 622/4885ALDH1A1 3727/4885KDM4E 3612/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 METAP2 3626/4885ALDH1A1 1507/4885KDM4E 3921/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B METAP2 2660/4885ALDH1A1 245/4885KDM4E 3158/4885
US-10174038-B2 Compounds and methods for antiviral treatment ZC3HAV1, SARS1, MAVS METAP2 622/4885ALDH1A1 3727/4885KDM4E 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.